Integrating network toxicology, machine learning, and experimental evidence reveals candidate targets and pathways in

Hanxiao Shen1, Wei Zhu2, Ding Wang1

  • 1Institute of Pharmaceutical Innovation, Hubei Province Key Laboratory of Occupational Hazard Identification and Control, School of Medicine, Wuhan University of Science and Technology, Wuhan, 430065, China.

Insights

Polychlorinated dibenzo-p-dioxins and dibenzofurans (PCDD/Fs) may increase colon cancer risk. This study reveals molecular mechanisms involving MMP7 and identifies potential therapeutic HSP90 inhibitors to reverse pollutant effects.

Area of Science:

  • Environmental Toxicology
  • Molecular Biology
  • Computational Biology

Background:

  • Carcinogenic polychlorinated dibenzo-p-dioxins and dibenzofurans (PCDD/Fs) are linked to increased colon cancer risk.
  • The precise molecular mechanisms driving PCDD/F-induced colon carcinogenesis are not fully understood.

Purpose of the Study:

  • To elucidate the molecular pathways through which PCDD/Fs promote colon cancer.
  • To identify potential therapeutic targets and compounds for mitigating PCDD/F-related colon carcinogenesis.

Main Methods:

  • Integrated network toxicology, machine learning, molecular docking, and molecular dynamics (MD) simulations.
  • In vivo mouse models were used to validate in silico findings.
  • Connectivity Map analysis was employed to identify potential therapeutic agents.

Main Results:

  • Machine learning identified MMP7 as a key target, upregulated in colon cancer and associated with immune infiltration.
  • Stable interactions were predicted between PCDD/F congeners and target proteins (MMP7, SRC, HSP90AA1).
  • In vivo TCDF exposure increased Mmp7, Hsp90aa1, and pro-inflammatory cytokines, while decreasing MUC2 expression in mice.

Conclusions:

  • PCDD/Fs promote colon carcinogenesis through specific molecular interactions and altered gene expression.
  • MMP7 and HSP90AA1 are identified as critical targets in PCDD/F-induced colon cancer.
  • Four HSP90 inhibitors demonstrate potential for reversing PCDD/F-induced molecular changes, offering therapeutic avenues.